The ability of AML cells to proliferate was reduced when TIM-3/gal-9 binding was inhibited in vitro [78], while in mice, an anti-human TIM-3 MoAb eradicated LSCs without damaging regular hematopoiesis [79]. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.